AAC · Insider Trading
Ares Acquisition Corporation III
Every open-market purchase and sale reported by AAC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2019-06-21 | Michael Nanko | President and COO | D | −33,334 | — |
| 2019-06-12 | Lucius E Burch III | Director | Buy | +150,000 | +$120.15K |
| 2019-06-12 | Lucius E Burch III | Director | Buy | +51,003 | +$41.31K |
| 2019-06-11 | Stephen Ebbett | See remarks | Buy | +55,549 | +$44.44K |
| 2019-06-06 | David C Kloeppel | Director | D | −45,454 | — |
| 2019-05-22 | W Larry Cash | Director | Buy | +10,000 | +$13.47K |
| 2019-04-26 | Michael J. Blackburn | Director | A | +90,908 | — |
| 2019-04-26 | Lucius E Burch III | Director | A | +90,908 | — |
| 2019-04-26 | David W. Hillis SR. | Director | A | +90,908 | — |
| 2019-04-26 | Darrell S. Freeman | Director | A | +90,908 | — |
| 2019-04-26 | W Larry Cash | Director | A | +90,908 | — |
| 2019-04-26 | David C Kloeppel | Director | A | +90,908 | — |
| 2019-04-26 | Jerry D. Bostelman | Director | A | +90,908 | — |
| 2018-12-03 | Michael Nanko | President and COO | Buy | +21,000 | +$45.87K |
| 2018-11-30 | W Larry Cash | Director | Buy | +25,000 | +$55.75K |
| 2018-11-30 | Darrell S. Freeman | Director | Buy | +25,000 | +$54.75K |
| 2018-09-28 | Stephen Ebbett | See remarks | A | +10,000 | — |
| 2018-05-24 | Michael T. Cartwright | Chairman and CEO | Sell | −100,000 | −$1.18M |
| 2018-05-08 | W Larry Cash | Director | Buy | +5,000 | +$59.55K |
| 2018-04-06 | Michael Nanko | President and COO | A | +50,000 | — |
| 2018-04-06 | Thomas W. Doub | Chief Clinical Officer and CCO | A | +10,000 | — |
| 2018-04-06 | Jerry D. Bostelman | Director | A | +7,000 | — |
| 2018-04-06 | Lucius E Burch III | Director | A | +6,500 | — |
| 2018-04-06 | Andrew W. McWilliams | Chief Financial Officer | A | +30,000 | — |
| 2018-04-06 | David C Kloeppel | Director | A | +7,500 | — |
| 2018-04-06 | Michael T. Cartwright | Chairman and CEO | A | +20,000 | — |
| 2018-04-06 | Darrell S. Freeman | Director | A | +8,500 | — |
| 2018-04-06 | Richard E Ragsdale | Director | A | +6,500 | — |
| 2018-04-03 | David C Kloeppel | Director | Sell | −5,000 | −$56.60K |
| 2018-03-15 | Michael T. Cartwright | Chairman and CEO | Sell | −100,000 | −$1.18M |
| 2018-03-15 | David C Kloeppel | Director | Sell | −5,000 | −$60.10K |
| 2018-03-08 | Michael J. Blackburn | Director | MIXED | −15,000 | −$180.00K |
| 2018-03-07 | W Larry Cash | Director | Buy | +5,000 | +$49.60K |
| 2018-02-28 | David C Kloeppel | Director | Sell | −5,000 | −$47.50K |
| 2018-01-30 | David C Kloeppel | Director | Sell | −10,000 | −$95.00K |
| 2018-01-03 | Kathryn Sevier Phillips | Chief Legal Officer, GC & Sec. | F | −2,733 | −$24.60K |
| 2018-01-03 | Michael T. Cartwright | Chairman and CEO | F | −2,669 | −$24.02K |
| 2018-01-03 | Kirk R. Manz | — | F | −1,821 | −$16.39K |
| 2018-01-03 | Andrew W. McWilliams | Chief Financial Officer | F | −2,961 | −$26.65K |
| 2018-01-03 | Thomas W. Doub | Chief Clinical Officer and CCO | F | −1,823 | −$16.41K |
| 2017-11-30 | W Larry Cash | Director | Buy | +10,000 | +$90.70K |
| 2017-11-15 | W Larry Cash | Director | Buy | +12,000 | +$119.16K |
| 2017-11-15 | Michael T. Cartwright | Chairman and CEO | Sell | −250,000 | −$2.41M |
| 2017-11-08 | Jerrod N. Menz | 10%+ Owner | Sell | −700,000 | −$7.15M |
| 2017-10-10 | Andrew W. McWilliams | Chief Accounting Officer | F | −136 | −$1.25K |
| 2017-10-03 | Kathryn Sevier Phillips | Chief Legal Officer, GC & Sec. | F | −910 | −$9.04K |
| 2017-10-03 | Andrew W. McWilliams | Chief Accounting Officer | F | −1,138 | −$11.30K |
| 2017-10-03 | Kirk R. Manz | Chief Financial Officer | F | −910 | −$9.04K |
| 2017-10-03 | Michael T. Cartwright | Chairman and CEO | F | −3,275 | −$43.40K |
| 2017-07-05 | Andrew W. McWilliams | Chief Accounting Officer | F | −1,102 | −$7.64K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AAC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.